
Opinion|Videos|October 30, 2025
CRC Screening Test Options
Advertisement
Episodes in this series

Advertisement
Related to this article

ObesityWeek 2026: Once-weekly semaglutide reduced BMI by 13.5% vs a 2.7% gain with placebo at 68 weeks in children 6 to <12 years with obesity.

The FDA approved at-home dexmedetomidine film for acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.

AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.

The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.

Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
Making Liver Fibrosis Testing Routine, With Zobair Younossi, MD, MPH
2
Sequential NITs Rule Out Advanced Fibrosis in Primary Care
3
Semaglutide Reduces BMI by 13.5% in Children Aged 6-11 in Step Young Trial
4
FDA Approves Dexmedetomidine as First At-Home Treatment for Acute Agitation
5

